{"id":"dorzolamide-timolol-maleate-fixed-combination","safety":{"commonSideEffects":[{"rate":"approximately 30-40%","effect":"Ocular burning or stinging"},{"rate":"approximately 10-15%","effect":"Blurred vision"},{"rate":"approximately 25-30%","effect":"Bitter taste"},{"rate":"approximately 5-10%","effect":"Ocular allergic reactions"},{"rate":"approximately 5%","effect":"Headache"},{"rate":"approximately 1-5%","effect":"Systemic beta-blocker effects (bradycardia, fatigue)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dorzolamide is a topical carbonic anhydrase inhibitor that decreases aqueous humor secretion in the eye by inhibiting the enzyme carbonic anhydrase II. Timolol maleate is a non-selective beta-adrenergic antagonist that reduces aqueous humor production and may increase uveoscleral outflow. The fixed combination provides complementary mechanisms to lower intraocular pressure more effectively than either agent alone.","oneSentence":"Dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while timolol blocks beta-adrenergic receptors to further decrease intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:57.168Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT05857267","phase":"PHASE4","title":"Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety","status":"COMPLETED","sponsor":"Laboratorios Poen","startDate":"2023-03-07","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":84},{"nctId":"NCT02053298","phase":"PHASE4","title":"Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-01","conditions":"Open Angle Glaucoma","enrollment":30},{"nctId":"NCT04673604","phase":"NA","title":"From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-05-06","conditions":"Glaucoma, Ocular Surface Disease","enrollment":42},{"nctId":"NCT00140049","phase":"PHASE4","title":"A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Open Angle, Ocular Hypertension","enrollment":238},{"nctId":"NCT00397241","phase":"PHASE4","title":"24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-09","conditions":"Open-angle Glaucoma","enrollment":33},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT01062971","phase":"PHASE2","title":"Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2006-02","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":124},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT00811850","phase":"PHASE4","title":"Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Glaucoma","enrollment":15},{"nctId":"NCT02325518","phase":"PHASE4","title":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2014-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":218},{"nctId":"NCT01471158","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-09","conditions":"Glaucoma","enrollment":120},{"nctId":"NCT00906594","phase":"PHASE4","title":"Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2007-09","conditions":"Glaucoma","enrollment":56},{"nctId":"NCT00379834","phase":"PHASE4","title":"12-Month Stability of Diurnal IOP Control on Cosopt","status":"COMPLETED","sponsor":"West Virginia University","startDate":"2006-09","conditions":"Glaucoma","enrollment":10},{"nctId":"NCT01175902","phase":"NA","title":"Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2011-03","conditions":"Normal Tension Glaucoma","enrollment":44},{"nctId":"NCT00972257","phase":"PHASE4","title":"24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-01","conditions":"Glaucoma","enrollment":64},{"nctId":"NCT01923714","phase":"","title":"Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2011-08","conditions":"Open Angle Glaucoma","enrollment":103},{"nctId":"NCT01655758","phase":"PHASE4","title":"24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension","status":"COMPLETED","sponsor":"University of Parma","startDate":"2002-01","conditions":"Ocular Hypertension","enrollment":61},{"nctId":"NCT00767481","phase":"PHASE3","title":"1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":6},{"nctId":"NCT00471380","phase":"PHASE4","title":"A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":46},{"nctId":"NCT00822055","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00822081","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2005-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00796198","phase":"PHASE4","title":"Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2008-12","conditions":"Glaucoma","enrollment":50},{"nctId":"NCT00273442","phase":"PHASE4","title":"Assessing Cosopt Switch Patients","status":"COMPLETED","sponsor":"Pharmaceutical Research Network","startDate":"2005-11","conditions":"Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome","enrollment":60},{"nctId":"NCT00273481","phase":"PHASE4","title":"Cosopt Versus Xalacom","status":"COMPLETED","sponsor":"Pharmaceutical Research Network","startDate":"2005-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":33},{"nctId":"NCT00273455","phase":"PHASE4","title":"Lumigan Versus Cosopt","status":"COMPLETED","sponsor":"Pharmaceutical Research Network","startDate":"2006-01","conditions":"Open-Angle Glaucoma","enrollment":34},{"nctId":"NCT00273429","phase":"PHASE4","title":"Cosopt Versus Xalatan","status":"COMPLETED","sponsor":"Pharmaceutical Research Network","startDate":"2005-04","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"dorzolamide/timolol maleate fixed combination","genericName":"dorzolamide/timolol maleate fixed combination","companyName":"Pharmaceutical Research Network","companyId":"pharmaceutical-research-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while timolol blocks beta-adrenergic receptors to further decrease intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}